Oct 27, 2026 Tang Capital reports a 9.6% passive stake Headline · Source: company release

Nasdaq: $EYPTWet-AMD pivotal missesDME Phase 3Cash and dilution

EYPT Stock Hub: EyePoint News, DURAVYU and the DME Trial Test

Both LUGANO and LUCIA missed their prespecified wet-AMD primary endpoint. Secondary and ad hoc findings remain separate evidence; DME Phase 3 and the cost of waiting now frame the development case. The October 29 regular-session close was $0.38 (+0.69% versus October 28).

Last updated: October 30, 2026Market reference: October 29, 2026 regular-session closeFinancial period: Historical June 30, 2026 statements; all original period labels retainedArchive reference: original page revision label October 30, 2026; original data dates retained; USD unless specified

Full research report · PDF

EyePoint ($EYPT), research as of October 30, 2026

17 pages covering the original long-form hub with its October 30, 2026 page revision label. Any separately dated later updates are reproduced unchanged; original data dates are retained. This is a dated research snapshot; the hub follows later developments. For personal use only: redistribution prohibited.

Get the report (PDF)

Next decisive company-guided clinical window

Q4 2027 · COMO and CAPRI Phase 3

EyePoint expects DME pivotal data in Q4 2027. This is a company window, without an exact readout date. Primary source

LUCIA reported October 19, 2026 and missed its primary endpoint; it is a completed readout, not an upcoming catalyst. The approximately 53% workforce reduction and spending priorities require execution.

EyePoint EYPT daily stock chart — Daily chart $EYPT. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

EYPT stock at a glance

Close · October 29, 2026

$0.38

Regular-session close; +0.69% versus $0.3774 on October 28.

Shares outstanding

86.21M

SEC 10-Q; July 31, 2026

Q2 liquidity

$180.5M

Cash and marketable securities, June 30

LUGANO primary endpoint

Missed

Prespecified full-dataset BCVA noninferiority analysis

LUCIA primary endpoint

Missed

Reported October 19; separate from the earlier LUGANO result.

Q2 ATM gross proceeds

$20.2M

Plus $17.5M gross in July

Q2 net loss

$94.5M

$1.09 per basic and diluted share

Next decisive event

DME Phase 3

COMO and CAPRI data expected in Q4 2027

Where EyePoint stands now

June cash, equivalents and marketable securities totaled $180.5M. Q2 net loss was $94.5M; Q2 ATM gross proceeds were $20.2M, followed by $17.5M gross in July. These historical resources and funding flows are not October cash. Primary source

Two pivotal misses raise the evidence burden while financing dilutes ownership.

The prespecified primary endpoint was missed, and the supportive p value of 0.0096 comes from an ad hoc analysis that excluded nine patients: regulators are not obliged to accept it. The quarterly net loss reached $94.5 million, the company drew on its at-the-market facility in the quarter and again in July, and short interest stood above 22% of the float.

The constructive case

LUGANO produced a 42% reduction in treatment burden and 54% of patients supplement-free through week 56, four holders above five per cent reported positions as of June 30, and a director bought in the open market in August. June 30 liquidity of $180.5 million and management’s earlier funding guidance covered the LUCIA readout, which has since been reported; the company announced a workforce reduction on October 19, and further financing and dilution remain possible.

The cautious case

Latest EyePoint news

October 27, 2026

Tang Capital reports a 9.6% passive stake

A Schedule 13G filed 2026-10-27 reports that Tang Capital beneficially owned 8,250,200 shares, representing 9.6% of the class as of October 20, 2026. This is a dated passive-ownership disclosure, rather than an acquisition announcement or a clinical result. The percentage uses the filing’s July 31 share count; affiliated reporting persons represent the same underlying holding.

SEC filing

October 19, 2026

LUCIA misses its primary endpoint; workforce cut by about 53%

EyePoint reported that the Phase 3 LUCIA study of DURAVYU in wet AMD did not meet its primary endpoint of non-inferiority, despite vision improvements and despite meeting key secondary endpoints including reduction in treatment burden, supplement-free rates, anatomic control and safety with redosing. The board approved a plan to reduce the workforce by approximately 53% and to conclude the pivotal Phase 3 wet AMD trials early, without full completion of the second year. The company will prioritize DURAVYU in diabetic macular edema, where the two Phase 3 trials (COMO and CAPRI, 551 patients) are expected to read out in the fourth quarter of 2027. Expected annualized savings are about $30 million, with one-time charges of about $9 million; estimated cash, cash equivalents and short-term investments were about $118 million at September 30, 2026.

Company announcement

September 16, 2026

Employee option award

EyePoint announced a September 15 grant of 3,000 options to one new employee at a $3.66 exercise price. The ten-year options vest 25% after one year and monthly over the next three years. They are potential future shares, not an issued-share increase.

Company announcement

September 10, 2026

Expanded LUGANO analyses published; primary endpoint remains missed

EyePoint filed an updated presentation with its September 10 Form 8-K. It adds median-regression analysis, modeled re-randomization scenarios and geographic-atrophy assessments to the LUGANO discussion. These are company exploratory analyses of preliminary data, not a new pivotal trial or a reversal of the failed prespecified primary endpoint. The previously reported exclusion of nine DURAVYU patients produced nominal noninferiority; it is not confirmatory evidence. LUCIA topline was reported on October 19, 2026 and did not meet the primary endpoint. The potential first-half 2027 NDA submission was described as a company plan dependent on positive LUCIA results and regulatory discussions.

SEC filing

August 17, 2026

LUGANO primary endpoint missed

The first wet-AMD pivotal trial did not meet its prespecified primary endpoint. Ad hoc analyses and treatment-burden observations are distinct from success on that endpoint.

Company announcement

August 5, 2026

Q2 accounts establish the historical financial base

EyePoint reported $180.5M cash and marketable securities at June 30 and a $94.5M quarterly net loss. The balance is historical, before subsequent events.

SEC filing

EYPT stock catalysts and operating watchpoints

Q4 2027 — COMO and CAPRI DME Phase 3 data expected. Company data window
Following October 19 prioritization — Implement workforce reduction and focus resources on DME development. Operating watchpoint
Next financial disclosure — Reconcile cash consumption and financing after the restructuring; no exact earnings date asserted. Financial watchpoint

Primary source

LUCIA Phase 3: The Replication Also Missed

Reported October 19, 2026 · 475 patients · NCT06683742

LUCIA is the identically designed companion pivotal study and uses the same blended weeks 52 and 56 BCVA noninferiority framework. Before LUGANO, it was the expected replication layer. After LUGANO’s primary-endpoint miss, it was the study most likely to determine whether EyePoint could still present a credible wet-AMD registration package. On October 19, 2026 the company reported that LUCIA did not meet its primary non-inferiority endpoint.

Financial Position: Stronger Than Many Binary Biotechs, but Burn Is High

EyePoint ended the second quarter of 2026 with $180.5 million in cash, cash equivalents and marketable securities, down from $222.5 million at March 31 and $306.1 million at December 31, 2025. Management kept its guidance that the current plan is funded into the fourth quarter of 2027, beyond the 2026 wet-AMD readouts and into the DME Phase 3 period. The runway is strategically useful, but it is a management estimate dependent on trial, manufacturing, launch-readiness and financing assumptions.

Q2 was a high-spend quarter. Revenue was only $0.507 million, compared with $5.333 million in Q2 2025, because historical YUTIQ deferred-revenue recognition had largely run off. R&D expense rose 51% year over year to $83.6 million, G&A increased 20% to $14.2 million and total operating expenses reached $97.9 million. The quarterly operating loss was $97.4 million and net loss was $94.5 million, or $1.09 per basic and diluted share.

Merlintrader Health Score · $EYPT

2.25out of 5

Balance sheet and runway · 30%2.0

$180.5 million of cash, equivalents and marketable securities at June 30, 2026, against a first-half net loss of $179.3 million, and a company financing itself through an at-the-market programme. Enough to reach the next readout; not enough to be indifferent to its outcome.

Catalyst · 30%3.0

LUCIA Phase 3 topline was reported on October 19, 2026 and also missed its primary endpoint, after the previous pivotal study of the pair had missed. The diabetic macular oedema programme (COMO and CAPRI) is the next readout, with topline expected by the company in the fourth quarter of 2027.

Dilution · 20%1.5

86,212,138 shares outstanding at July 31, 2026, with at-the-market issuance in the second quarter and again in July. On a share price near $3, funding the wait costs materially more of the company than it did a year ago.

Liquidity · 10%2.0

The October 29 regular-session close was $0.38. The historical liquidity score is retained; price alone does not establish spread, depth or future returns.

Execution · 10%2.5

Both wet-AMD pivotal trials were enrolled and both have now reported: LUGANO and LUCIA each missed their prespecified primary endpoint. The diabetic macular oedema programme is fully enrolled, demonstrating enrollment execution. Against that, the first pivotal readout missed its prespecified primary endpoint, and the company presented an ad hoc analysis alongside it.

Assessed October 4, 2026. Weighted calculation: 2.0×30% + 3.0×30% + 1.5×20% + 2.0×10% + 2.5×10% = 2.25. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

Financial balances retain their reporting dates and are not current cash.
Milestone guidance is conditional; execution, collection and per-share outcomes remain separate tests.

EYPT Stock FAQ: EyePoint Questions Answered

Did LUGANO succeed or fail?

It failed on its prespecified primary endpoint. In the full analysis set, DURAVYU did not demonstrate prespecified best-corrected visual acuity non-inferiority against aflibercept. EyePoint separately reported nominal non-inferiority in an ad hoc analysis that excluded nine of 211 DURAVYU patients whose losses of at least 15 letters were judged unrelated to wet AMD. The prespecified primary outcome and the ad hoc result have different evidentiary weight.

When did LUCIA read out?

EyePoint reported LUCIA Phase 3 topline on October 19, 2026: the study did not meet its primary non-inferiority endpoint. LUCIA is the second of the two pivotal wet AMD studies. The company is prioritizing DURAVYU in DME, where COMO and CAPRI topline is expected in the fourth quarter of 2027.

What is DURAVYU?

DURAVYU, also known as EYP-1901, is an investigational sustained-delivery treatment for VEGF-mediated retinal diseases, combining vorolanib, a tyrosine kinase inhibitor, with EyePoint’s bioerodible Durasert E technology. The argument for it is treatment burden: fewer injections than the standard of care.

How much cash does EyePoint have?

Cash, equivalents and investments in marketable securities were $180.5 million at June 30, 2026, against a first-half net loss of $179.3 million, up from $104.6 million in the same period of 2025. The company raised further money through its at-the-market programme in the second quarter and again in July.

Is this page a recommendation to buy or sell $EYPT?

No. This Stock Hub is informational and educational. It sets out dated facts, their sources and the scenarios they leave open. It does not recommend any action.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $EYPT or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.

This Stock Hub is provided exclusively for informational and educational purposes. It is not regulated investment research, personalized financial advice, a solicitation, or a recommendation to buy, sell or hold EyePoint or any other security. Biotechnology stocks can experience extreme volatility around clinical, regulatory, manufacturing and financing events. Company guidance, trial timelines, ClinicalTrials.gov dates, analyst targets, cash-runway estimates and forward-looking statements can change without notice. Readers must independently verify all information through EyePoint filings, official company releases, ClinicalTrials.gov, FDA materials and other primary sources, and must evaluate their own financial situation, risk tolerance and investment horizon. Merlintrader and the author do not guarantee the accuracy, completeness or continued validity of third-party data or forward-looking statements. Analyst price targets cited in market commentary are opinions and are not Merlintrader forecasts. Nothing on this coverage should be interpreted as advice under U.S. SEC or FINRA standards or under Italian and European rules supervised by CONSOB and other competent authorities.

EYPT Stock Hub: EyePoint News, DURAVYU and the DME Trial Test

EYPT stock at a glance